Screener
Xeris Biopharma Holdings, Inc. XERS Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Total current assets | 274,757 | 240,313 |
| Property and equipment, net | 4,834 | 4,945 |
| Operating lease right-of-use assets | 21,773 | 22,112 |
| Goodwill | 22,859 | 22,859 |
| Intangible assets, net | 82,657 | 88,078 |
| Other assets | 5,025 | 5,220 |
| Total assets | $411,905 | $383,527 |
| Liabilities and Stockholders' Equity |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s goodwill?
- Xeris Biopharma Holdings, Inc. (XERS) reported goodwill of $22.86M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s goodwill changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s goodwill decreased by 0.0% year-over-year, from $22.86M to $22.86M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about Xeris Biopharma Holdings, Inc.'s goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude